SLC5A2 and diabetes mellitus: Misclassification of SGLT2 inhibitors as diabetes-only medications was prevalent among insurance physicians (61.2%) and the strongest predictor of rejection (adjusted OR 0.18, 95% CI 0.10-0.33).